{ "id": "lymph-node", "title": "Lymph node", "lang": "en", "source_lang": "en", "summary": "A lymph node is a small, encapsulated organ of the lymphatic system that filters lymph and hosts immune cells that start adaptive immune responses.", "category": "health", "subcategory": "anatomy-physiology", "type": "concept", "aliases": [ "lymph gland", "lymphatic node" ], "generated_at": "2026-10-08", "model": "pro/claude-haiku-5-5", "url": "https://aiwiki.page/en/lymph-node/", "translations": { "zh-Hans": { "url": "https://aiwiki.page/zh/lymph-node/", "json": "https://aiwiki.page/zh/lymph-node.json" } }, "sections": [ { "heading": "", "text": "A lymphatic system lymph node is a small, usually bean-shaped organ, encapsulated in connective tissue and scattered along the lymphatic vessels. Each node receives lymph from a particular region of the body, filters it, and holds dense populations of lymphocytes, macrophages and dendritic cells. Together with the spleen, thymus and other lymphoid tissues, nodes form the secondary lymphoid organs where immunity is organized.\n\nLymph nodes matter because they are the main sites where adaptive immune responses begin. Antigens picked up in tissues are carried to nodes, where T cells and B cells are activated and germinal centres generate antibodies with higher affinity over time. In medicine, nodes are equally important as signals: enlargement often indicates infection, inflammation, lymphoma or spread of cancer, and the pattern of node involvement guides staging, surgery and radiotherapy.\n\nThis entry first describes what a lymph node is, where the body's nodes are located and how they are built at the microscopic level. It then follows lymph flow through the nodes, their role in immune responses and lymphocyte recirculation, and their development. The final sections cover clinical examination and diagnosis, common diseases, metastasis and staging, the history of discovery, surgical and imaging techniques, and open questions in research." }, { "heading": "Definition and basic structure", "text": "A lymph node is a small, encapsulated organ located along the course of the lymphatic vessels. Its outer layer is a fibrous capsule of dense connective tissue, and thin trabeculae extend from it into the interior, partly dividing the node into compartments. Several afferent lymphatic vessels carry lymph into the node through the convex outer surface, while efferent vessels carry it out. The concave surface has a notch called the hilum, through which the node's arteries and veins enter and leave. The blood supply and the outflow of lymph therefore meet at the same point, even though the two circulations are separate.\n\nMost adult nodes are bean-shaped and small. In most regions, a normal node measures well under 1 cm in its short axis, while inguinal nodes can be somewhat larger in healthy people. Nodes are not evenly distributed. Superficial groups in the neck, armpit and groin lie in thin subcutaneous fat, close to the skin and without thick muscle over them, so healthy nodes there can sometimes be felt as small, firm, mobile and painless structures. Deep nodes in the chest, abdomen and pelvis sit beneath muscles and organs and cannot normally be palpated. The total number of nodes is usually estimated in the hundreds, but counts vary considerably between individuals, a point discussed in the anatomical distribution section.\n\nInternally, a node is organized around a three-dimensional meshwork of reticular fibres, a form of collagen (type III) that is laid down by specialized stromal cells, chiefly fibroblastic reticular cells. This scaffold is not a passive frame. It holds the dense population of lymphocytes, along with dendritic cells and macrophages, in fixed positions while leaving channels through which lymph and cells can move. The stromal network also carries signalling molecules that help determine where different cell types settle, which is why the node's internal zones are so well defined.\n\nLymph nodes belong to the group of secondary lymphoid organs, which are the sites where mature lymphocytes encounter antigens and begin adaptive immune responses. Other members include the spleen, the tonsils and Peyer's patches. The spleen is also encapsulated, but it filters blood rather than lymph and has no comparable afferent lymphatic supply. Its white pulp is arranged around arteries, and its red pulp removes damaged red blood cells. The tonsils and Peyer's patches are not encapsulated. They are aggregates of lymphoid follicles beneath the mucosal epithelium of the pharynx and small intestine, where they sample antigens that arrive across the mucosal surface, with Peyer's patches using specialized M cells for this purpose. Nodes differ from these organs in that they are reached by lymph from the tissues they drain. Together with the thymus and bone marrow, which are primary lymphoid organs where lymphocytes develop, they form the body's organized lymphoid system." }, { "heading": "Anatomical distribution and drainage regions", "text": "Lymph nodes are not spread evenly through the body. Their distribution follows the paths of the lymphatic system: each node sits where lymph from a particular territory converges. Standard atlases group the regional nodes by location: the head and neck (occipital, parotid, submandibular and cervical chains, plus the pharyngeal and palatine tonsillar nodes of Waldeyer's ring), the axilla, the epitrochlear and supratrochlear nodes of the arm, the mediastinum (hilar, tracheobronchial and paraoesophageal nodes), the abdomen (para-aortic, mesenteric, common, external and internal iliac, and rectal nodes), and the groin. A typical young adult has up to about 450 nodes, with roughly 60–70 in the head and neck, about 100 in the chest and as many as 250 in the abdomen and pelvis. Most of the abdominal nodes lie against the viscera, especially in the mesentery of the intestines.\n\nSuperficial and deep groups\n\nSuperficial nodes lie beneath the skin and in the subcutaneous tissue, and they are the ones most often examined in clinical practice. The cervical nodes along the jaw and the sides of the neck, the axillary nodes in the armpit and the inguinal nodes at the groin crease belong to this group. Deep nodes sit around major vessels and inside the chest and abdomen, where they cannot be felt in a healthy person. The superficial inguinal nodes are subdivided into upper medial, upper lateral and lower vertical groups, and they receive lymph from the skin and fascia of the lower limb, buttock, external genitalia and lower abdominal wall. Their efferent vessels then pass to the deep inguinal nodes, which also collect drainage from the deep tissues of the leg and the glans penis. In the neck, the deep lateral cervical nodes lying beside the internal jugular vein receive most of the lymph from the head and neck before it drains into the jugular trunk.\n\nDrainage patterns and clinical relevance\n\nEach body region sends its lymph to a predictable node group, which is why the location of an enlarged node helps to localize a problem. The skin of the lower abdomen above the umbilicus drains toward the axilla, while tissue below the umbilicus drains to the superficial inguinal nodes; the umbilicus therefore marks a watershed where the two channels do not cross. The axillary nodes are arranged in five groups (lateral, anterior or pectoral, posterior or subscapular, central and apical). Most of the lymph from the upper limb enters the lateral group, and the central group, which lies at the base of the axilla, is the main collecting station for the breast. This is why breast cancers commonly spread to the axillary nodes and why the axilla is examined carefully in breast disease. Lymph from the ulnar side of the hand and forearm is an exception: it first reaches the epitrochlear nodes above the elbow. Lymph from the lungs passes through segmental and hilar nodes before reaching the mediastinal nodes. These predictable routes are the basis for tracing infections, such as a lymphadenitis following a foot wound, and for predicting where tumours will spread, a topic discussed under cancer and in the staging section.\n\nVariation and the difficulty of counting\n\nPublished estimates of the total number of nodes differ widely. Some sources give about 450 for a young adult, while others give 400–800 or 500–600 for adults in general. Such variation is normal, and it depends on body size, genetics, age and the history of immune exposure. Counting is also difficult because the boundary between a small node and a lymphoid nodule is not always clear, and because many nodes are tiny, deep and embedded in fat. Their number and position also differ between individuals: some people have more nodes in one region, and some nodes are absent or fused. Counts from dissection, imaging and historical anatomical texts therefore do not always agree. Because of this, the total is best understood as a range rather than as a fixed number, and regional groups are more reliable as anatomical units than individual nodes." }, { "heading": "Microanatomy and internal zones", "text": "Inside its fibrous capsule, a lymph node is organized into concentric compartments: an outer cortex, a T-cell-rich paracortex (deep cortex), and an inner medulla. Fibrous trabeculae that extend inward from the capsule partition the cortex into lobules. In larger mammals and humans there are ten or more of these, and each one contains a follicle plus the adjacent paracortical tissue. The sinus system threads through all of these compartments, so the lobules sit within it somewhat like islands in a stream.\n\nOuter cortex and follicles\n\nThe outermost layer is the cortex, which contains the subcapsular sinus, the cortical sinuses and the lymphoid nodules. The subcapsular sinus is the first space that lymph from the afferent vessels reaches inside the node. Lymphoid follicles fill much of the cortex. Primary follicles consist mostly of immature lymphocytes, whereas secondary follicles, formed after antigen encounter, are rich in B cells and contain germinal centres where B cells expand and mature. The superficial cortex, made up of follicles and the interfollicular tissue between them, is the region where antigen is first sampled.\n\nParacortex\n\nBeneath the follicles lies the paracortex, dominated by mature T cells and dendritic cells. Its basic structural unit is the paracortical cord, a cylinder with a central high endothelial venule (HEV) surrounded by concentric layers of fibroblastic reticular cells (FRCs) and bordered by a cortical sinus. These cords start at the base of the follicles, run parallel through the cortex, and merge into medullary cords at the corticomedullary junction. HEVs are lined by cuboidal rather than flat endothelium, and lymphocytes attach to this lining before squeezing through into the deep cortex. Transmigration is concentrated along the widest HEV segments deep in the paracortex. At the corticomedullary junction, HEVs revert to ordinary venules with flat endothelium.\n\nMedulla\n\nThe medulla lies near the hilum, where it forms a loose network of medullary cords and sinuses, separated from the paracortex by connective tissue fibres. Medullary cords hold both T and B cells and most of the node's plasma cells, which are a major source of secreted antibody. The medullary sinuses are the final channels through which lymph passes before it leaves by efferent vessels, and they contain macrophages that help clear material from the fluid. Medullary venules carry blood out of the node through the hilum.\n\nStromal networks and the conduit system\n\nThe architecture of each zone depends on a stromal scaffold. The capsule and trabeculae are built from dense connective tissue, and the trabeculae continue into the interior as fine reticulin fibrils of type III collagen. Within the paracortex and the follicles, the stroma is formed by FRCs, which secrete extracellular matrix and form a mesh-like network. T-zone FRCs produce the chemokines CCL19 and CCL21, which attract CCR7-expressing naive T cells and dendritic cells, and they also secrete IL-7, a cytokine needed for naive T cell survival. FRCs ensheath a conduit system of collagen tubes, roughly 3D-mapped in mice, that carries small soluble molecules from the afferent lymph toward the paracortex and HEVs. Conduit density is higher in the superficial T-cell zone than in the deep zone. FRCs are not a single population: distinct subsets occupy the marginal zone, the follicles (where follicular dendritic cells arise), the T–B border, the T-cell zone and the perivascular space. In mouse experiments, FRCs have also been shown to restrain T-cell expansion through nitric oxide production, which indicates that the stroma regulates immune responses as well as supporting them." }, { "heading": "Lymph flow, filtration and drainage", "text": "Route through the node\n\nLymph reaches a node through afferent vessels, which pierce the fibrous capsule on the convex side and open into the subcapsular sinus, a channel that runs beneath the capsule and surrounds the node. From there, fluid moves inward through trabecular (intermediate) sinuses that run along the connective-tissue septa of the cortex, and then reaches the medullary sinuses, which lie between the medullary cords. The medullary sinuses converge toward the hilum, where they join to form efferent lymphatic vessels that carry lymph out of the node. Because the sinuses are interconnected and the septa have openings, lymph can pass between neighbouring channels rather than following a single fixed path. Some lymph also leaves through efferent vessels arising from the interfollicular and deep cortical sinuses, so the exit pathway has more than one entry point. Each of these spaces is crossed by a meshwork of reticular fibres and reticular cell processes, which slows the fluid and increases its contact time with the cells lining the channels.\n\nFiltration by resident cells\n\nThe sinuses are not empty conduits. Macrophages line the floor of the subcapsular sinus, sitting directly over the B-cell follicles, and similar macrophages are abundant along the medullary sinuses, where they have often engulfed material. Dendritic cells in the sinus spaces sample particles and microbes carried in the lymph. As a result, the node acts as a filter that removes bacteria, viral particles, cell debris and other foreign material before lymph returns to the blood. Captured antigens are held in a form that lymphocytes can recognise, which links this filtering function to the immune responses described in other sections. The reticular meshwork and the slow flow through the sinuses together make this capture more efficient.\n\nPropulsion and one-way flow\n\nLymph moves through a low-pressure system, far below the pressure of the arterial circulation, so its movement depends on several mechanisms working together. Smooth muscle in the walls of larger lymphatic vessels contracts in a rhythmic, peristaltic manner. Skeletal muscle contraction compresses the vessels, and the pulsation of nearby arteries and the movements of breathing also help push fluid onward. Lymphatic capillaries begin as blind-ended tubes whose endothelial cells overlap loosely, forming tiny one-way flaps that let fluid enter but not leave. Larger collecting vessels contain valves, and their wall structure resembles that of veins; the valves produce a beaded appearance because each one causes a small swelling. These valves together ensure that lymph moves steadily toward the central circulation.\n\nReturn to the venous system\n\nThe lymphatic vessels from the body are collected into lymphatic trunks named for the region they drain, including jugular, subclavian, bronchomediastinal and lumbar trunks, plus a single intestinal trunk. These trunks feed two main ducts. The right lymphatic duct receives lymph from the upper right quarter of the body, including the right arm, the right side of the head and neck, and the right thorax, and empties into the right venous angle at the junction of the right subclavian and internal jugular veins. The thoracic duct is larger and collects lymph from the rest of the body. It begins as a sac-like chamber, the cisterna chyli, just below the diaphragm, which receives lymph from the lower limbs, pelvis and abdomen, including chyle from the intestine. The thoracic duct then ascends through the chest and empties into the left venous angle, near the junction of the left subclavian and internal jugular veins. A valve at its opening prevents blood from flowing back into the duct. Because of this arrangement, filtered lymph is returned to the bloodstream at the upper chest, and the asymmetry between the two ducts is a standard feature of human anatomy. In some individuals the duct branches and joins in more varied ways, so the exact course of the thoracic duct is not fully predictable." }, { "heading": "Immune function and lymphocyte recirculation", "text": "Antigen presentation in the paracortex\n\nLymph nodes are where the adaptive immune system samples what the body has encountered. Antigens reach a node mainly in two ways: as free molecules carried in afferent lymph, and as material taken up by dendritic cells in peripheral tissues. Dendritic cells that have picked up antigen and matured move along the afferent lymphatics into the node, where they express the chemokine receptor CCR7 and settle in the T-cell-rich paracortex. There they display processed peptides on MHC molecules: MHC class II for CD4 T cells, and MHC class I for CD8 T cells, often through cross-presentation of material taken up from other cells. A naive T cell that recognises its specific peptide through its T-cell receptor is activated, receives costimulatory signals, and begins to proliferate. Its progeny differentiate into effector cells, and some become memory cells. Because this process depends on rare antigen-specific clones meeting the right presenting cell, the node's architecture helps concentrate the encounters.\n\nB-cell responses in follicles and germinal centres\n\nB cells are activated in the follicles of the outer cortex. A B cell whose B-cell receptor binds antigen moves toward the boundary with the paracortex, where it can receive help from T follicular helper cells. The response then follows one of two broad routes. In an extrafollicular response, short-lived plasma cells are produced quickly, with limited affinity improvement and limited class switching. In the second route, a germinal centre forms within the follicle. In its dark zone, B cells proliferate and undergo somatic hypermutation of their immunoglobulin variable-region genes. They then move to the light zone, where follicular dendritic cells display immune complexes and T follicular helper cells select the clones whose receptors bind antigen most tightly. Selected cells re-enter the dark zone or leave as memory B cells or antibody-secreting plasma cells. Class switching, which changes the constant region of the antibody heavy chain from IgM to IgG, IgA or IgE, depends largely on CD40 signalling from T follicular helper cells together with cytokines. Defects in the enzymes and receptors involved cause immunodeficiencies, such as hyper-IgM syndromes, in which these steps fail.\n\nLymphocyte recirculation\n\nLymphocytes do not remain in one node. Naive T and B cells enter most nodes from the blood through specialised postcapillary venules called high endothelial venules (HEVs). Their entry depends on L-selectin binding to vascular addressins on HEVs, followed by CCR7 engagement by the chemokines CCL19 and CCL21, which activates the integrin LFA-1 so that it binds ICAM-1 and ICAM-2 on the endothelium. Once inside, the cells scan the paracortex and follicles for antigen. Those that do not encounter their antigen leave the node through efferent lymphatic vessels, carried by the lymph flow into the lymphatic system and back to the blood. Recirculation of this kind allows a naive cell to be exposed to many nodes over time, which increases the chance that it meets its antigen. Effector and memory T cells, by contrast, can enter nodes from peripheral tissues through afferent lymphatics, which carries them into the node carrying information about infection or inflammation at distant sites.\n\nMolecular control of migration\n\nMovement through the node is governed by a balance between chemokine signals and lipid signals. Naive lymphocytes express high levels of CCR7 and low levels of the receptor for sphingosine-1-phosphate (S1PR1), which favours retention in the node. S1P concentration is low in node tissue, partly because of degradative enzymes, but high in lymph and blood. Lymphocytes that encounter S1P at high concentration in efferent lymph follow this gradient out of the node. Chemokine and S1P receptors are regulated by the cells themselves: exposure to a ligand leads to receptor internalisation and transient desensitisation, and the receptor is re-expressed later. This cycle lets a cell alternate between phases of retention and egress. Adhesion molecules, such as selectins, integrins and their ligands, control how cells tether to and cross the endothelium, and their expression changes when a cell is activated. Effector cells lose CCR7 and L-selectin and gain other homing receptors, which directs them to sites of infection or inflammation. Together these mechanisms allow nodes to continuously sample the body for antigen, which is the basis of immune surveillance in the lymphatic system." }, { "heading": "Development and formation", "text": "Mammalian lymphatic vessels are traced to embryonic veins, and lymph nodes develop within this vascular framework. In mice, the transcription factor SOX18 appears in cardinal vein endothelium around embryonic day (E)9.5 and acts upstream of PROX1, which becomes the master regulator of lymphatic fate by about E10.5 SOX18, in turn, induces the expression of PROX1, a master controller of lymphatic endothelial cells fate at E10.5. Starting near E11.5, cells that express both factors detach from the vein and migrate outward to form jugular lymph sacs. Loss-of-function experiments confirm the sequence. Sox18-null embryos show a complete blockade of lymphatic endothelial cell differentiation from the cardinal vein. Embryos lacking Prox1 are also affected: budding stalls around E11.5, leaving them without a lymphatic network. A gain-of-function variant of RAF1, linked to Noonan syndrome, pushed more venous endothelial cells toward a lymphatic identity in mice, showing how signaling inputs feed into this lineage choice.\n\nOrganizer cells and the start of node formation\n\nThe node program starts from a different population. In the classical two-cell model, LTi cells regulate the activation of mesenchymal organizer cells. Recent mouse work has added lymphatic endothelial cells as a third participant that initiates node formation. The earliest visible step is the clustering of LTi cells at the future node site, and attraction to this location is regulated by expression of CXC-chemokine ligand 13 (CXCL13). One study proposed that nearby nerve fibers help induce this chemokine through retinoic acid. LTi cells are a hematopoietic population marked by RORγt and IL-7Rα expression. They carry lymphotoxin α1β2, which engages lymphotoxin-β receptor (LTβR) on stromal organizers. Once activated, the stromal cells increase adhesion molecule expression and produce the chemokines CXCL13, CCL19 and CCL21, which recruit and retain hematopoietic cells. In mice and humans alike, this prenatal crosstalk drives node development. Nodes also tend to form where blood vessels branch.\n\nGenetic dependence and diversity between sites\n\nGenetic evidence shows how central this pathway is. Mice deficient in LTβR also lack lymph nodes and Peyer's patches. Different cytokines induce lymphotoxin on IL-7Rα-expressing cells in ways that favor either node or Peyer's patch formation, so the two organs are not simply variants of one program. Mucosal lymphoid tissues form by a different route again. The capacity for lymph node formation appears restricted to placental mammals. Spleen organizers were characterized much later: little is known about the equivalent stromal cells that induce spleen development. Here, by dissociating neonatal murine spleen stromal tissue for re-aggregation and transplant into adult mouse recipients, we have identified a stromal population critical for new tissue formation. Variation among species and sites, and the effects of mutations in these genes, therefore reflect different organizer and signaling requirements rather than a single template.\n\nPostnatal maturation\n\nNodes continue to mature after birth, and antigen exposure strongly shapes this process. In newborn mice, nodes look structurally immature, with few lymphocytes and little follicular dendritic cell network, whereas adult nodes have crowded B-cell follicles and extensive FDC networks. Immunizing mice on the day of birth speeds up B-cell accumulation in follicles, FDC maturation and organization of fibroblastic reticular cells. However, the formation of germinal centers was both delayed and reduced following immunization of neonatal mice. Isotype switching also remains behind adult levels. Earlier rat experiments showed the same dependence on antigen: in stimulated popliteal nodes, the first secondary follicles, containing germinal centers, were detected at day 23, whereas in unstimulated popliteal lymph nodes they were never found. Because fibroblastic reticular cells allow nodes to restructure after inflammation, the architecture remains responsive to exposure throughout life." }, { "heading": "Clinical examination and diagnosis", "text": "Palpation and the bedside assessment\n\nMost enlarged nodes are first found by touch. The examiner relaxes the area so the node can be separated from muscle and tendon, then palpates each drainage region with the fingertips. Four features are recorded: size, consistency, tenderness and mobility or fixation to the underlying tissue. Tender, warm, erythematous nodes usually point to a local inflammatory cause. Nodes that are firm, non-tender, matted together or fixed to deeper structures raise concern for malignancy, although this distinction is not absolute. Certain sites carry more weight. Supraclavicular and epitrochlear enlargement are treated as red flags, and an enlarged node in the supraclavicular or axillary region is worth investigating whatever its size. Mediastinal, retroperitoneal and mesenteric nodes are usually not palpable and are suspected instead when they compress nearby structures.\n\nClinicians also look for systemic clues. Fever, night sweats, weight loss and splenomegaly suggest infection, lymphoma or leukaemia, while a history of tuberculosis or HIV risk, sexual exposures, travel, animal contact and medication use can narrow the list of causes. Lymphadenopathy is classed as localized when one region is involved and as generalized when two or more regions are affected, and generalized disease more often reflects a systemic process. Benign nodes commonly regress within about four to six weeks, so persistent or progressive enlargement prompts further work-up. Corticosteroids should be avoided before a diagnosis is established, because they can mask the histological features of lymphoma.\n\nImaging\n\nUltrasonography is usually the first imaging study for superficial nodes. A normal node tends to keep a visible fatty hilum and a hypoechoic cortex with orderly blood flow. Features suggesting malignancy include a rounded shape (a short-to-long axis ratio approaching one), irregular or indistinct borders, loss of the hilum and abnormal vascularity. Conventional thresholds apply to cross-sectional imaging. On CT and MRI, a short-axis diameter of about 10 mm is the usual cut-off for cervical, axillary and mediastinal nodes, and abdominal nodes larger than about 10 mm are generally considered pathological. These size-based criteria are imperfect. Some studies have proposed lower thresholds, and a meaningful fraction of metastatic nodes in some tumour types measure under 10 mm. Shape, margin, necrosis and enhancement pattern can add information beyond size.\n\nPET combined with CT adds functional information. Because malignant cells often take up the glucose tracer strongly, PET can flag involved nodes of normal size, which is a key advantage over CT. Its limitations are spatial resolution, which makes very small deposits hard to detect, and false positives, since infection and inflammation also concentrate the tracer. Sensitivity for subcentimetre nodes in one lung-cancer series was high while specificity was modest. For some lymphoma subtypes with low tracer uptake, CT size remains the main criterion.\n\nTissue sampling\n\nWhen imaging or clinical features remain suspicious, tissue is obtained. Fine-needle aspiration is quick, inexpensive and minimally invasive, and it is often sufficient to identify metastatic carcinoma or granulomatous disease. For suspected lymphoma it is inadequate on its own, because the pathologist needs intact tissue to judge the architecture of the node. Core-needle biopsy preserves more structure and is now widely used, but it can produce non-diagnostic results. In a systematic review, only about three-quarters of aspirates and core samples gave a subtype-specific lymphoma diagnosis, and roughly a quarter to a third still needed excisional biopsy. Excision therefore remains the reference standard for lymphoma classification. Diagnostic material is examined by pathologists using morphology, immunohistochemistry and immunophenotyping to identify lineage, and flow cytometry or molecular tests assess clonality. Axillary and inguinal biopsies carry higher risks of infection, lymphocele and neurovascular injury than cervical or supraclavicular sampling, so the most abnormal, largest or firmest node in an accessible site is generally chosen.\n\nGeneralized versus localized disease and the clinical clues\n\nLocalized lymphadenopathy is usually explained by the drainage territory: an infected finger produces axillary nodes, and a leg infection produces inguinal or popliteal nodes. Generalized enlargement needs a broader search that often includes blood counts, serological and viral tests, and sometimes bone marrow assessment. Some drugs, including phenytoin, allopurinol and certain antibiotics, cause nodal enlargement, so medication history matters. Infection, autoimmune disease and lymphoma or leukaemia are the main categories to separate, with the combination of duration, distribution, systemic symptoms and examination findings guiding which investigation comes next. Most cases are benign, but persistent nodes with red-flag features are the reason for timely biopsy." }, { "heading": "Common diseases and pathological changes", "text": "Lymph nodes sit downstream of most tissues and sample the lymph that drains them, so local infections, systemic illnesses, drugs and cancers can all alter their size, architecture or cellular content. Most enlarged nodes are reactive rather than neoplastic. When resident cells multiply in response to antigen, the enlargement is classed as reactive lymphadenopathy, reflecting antigenic stimulation.\n\nReactive lymphadenitis\n\nThe histological response depends largely on the trigger. Inflammatory change is the usual reaction to bacterial and fungal invaders, while viruses and some drugs more often provoke an immune-type response Bacteria and fungi cause predominantly inflammatory reactions; viruses and drugs cause predominantly immune reactions.. With pyogenic organisms such as staphylococci and streptococci, neutrophils are recruited into the node, and rapid swelling, distension of the capsule, edema, and potential tissue necrosis, along with the risk of abscess formation can follow.\n\nPathologists classify reactive nodes by their dominant architectural pattern. The reactive lymphadenopathies are grouped into four major categories according to their predominant architectural histologic pattern: follicular-nodular, sinus, interfollicular or mixed, and diffuse. Clinically, the timing of symptoms helps: recent swelling is typically sore, whereas long-standing enlargement is often painless Acute: painful or tender; chronic: nontender. Common triggers include upper respiratory infections, stomatitis, or dental caries, many viral infections including HIV, infectious mononucleosis, and CMV, and drugs such as phenytoin and carbamazepine.\n\nTuberculosis and HIV infection\n\nTuberculosis remains an important cause of nodal enlargement, particularly in the neck, where characteristics of tuberculous lymph nodes include being clustered or stuck together, painless, and having a smooth surface. Histologically, caseating granulomas are the typical finding, a feature that is not captured by the clinical description alone.\n\nIn HIV infection, generalised enlargement often reflects an early reactive state. In one case report, a few hyperplastic follicles, such as usually seen in HIV-infection-associated lymphadenopathy, were present at the periphery of one lymph node. In more advanced disease, follicular architecture tends to become depleted as CD4 T cells decline.\n\nLymphoma and leukaemia\n\nGeneralized lymphadenopathy suggests underlying systemic disease caused by infection (eg, infectious mononucleosis), malignancy (eg, lymphoma), or autoimmune disorders (eg, systemic lupus erythematosus). Lymphomas and leukaemias infiltrate nodes directly. Hodgkin lymphoma is defined by Reed–Sternberg cells within an inflammatory background, whereas non-Hodgkin lymphomas form a heterogeneous group of B-cell and T-cell tumours with widely differing behaviour. Diagnosis therefore depends on architecture, cytology and immunophenotyping together rather than on morphology alone. Some nodes called reactive on morphology have often been diagnosed as reactive lymphadenitis, but later found to be of specific pathologic processes, which is why ancillary testing matters.\n\nHistiocytic and inflammatory disorders\n\nSinus histiocytosis with massive lymphadenopathy, also called Rosai–Dorfman disease, was initially described by Destombes in 1965 under the term \"adenitis with lipid excess.\" However, it is named after Rosai and Dorfman who reported further histopathological features of the disease in 1969. It typically presents with bilateral painless cervical lymphadenopathy, fever, and leukocytosis identified on blood examination. The hallmark diagnostic features are emperipolesis and positive S100 and CD68 markers. Its cause is unknown, and the two leading causes being autoimmune dysregulation or histiocytic proliferation secondary to infection have been proposed. Many patients have a favourable course, and about half of cases resolve spontaneously.\n\nKikuchi–Fujimoto disease, or necrotising histiocytic lymphadenitis, was first described in 1972 by Japanese pathologists Kikuchi and Fujimoto, and it is most often reported in Asian populations, mainly in young women it is known for its low incidence and misdiagnosis that occurs mostly in young Asian females more than males. Histologically, it shows paracortical lesions with varying degrees of necrosis, crescentic histiocytes containing nuclear debris, and CD8-positive T cells. The proliferative form predominates in most series, and the disease is self-resolving in a few months with a low risk of relapse. Because it overlaps clinically with lymphoma, tuberculosis and lupus, these features are important in distinguishing KFD from conditions such as non-Hodgkin lymphoma, tuberculosis, and lupus lymphadenitis. Autoimmune disease can also coexist; in one series, association with autoimmune diseases was shown by 20.5% of cases.\n\nAutoimmune disorders can also reshape nodes directly. Rheumatoid arthritis and Sjögren syndrome, for example, are listed among conditions that produce reactive follicular patterns The morphologic pattern of RFH often occurs in association with benign and reactive etiologies, including autoimmune disease (for example, rheumatoid arthritis, Sjögren syndrome and Kimura disease).\n\nLymphoedema\n\nLymphoedema is swelling caused by impaired lymphatic drainage. Secondary forms are the most common in clinical practice and arise after lymph node removal during cancer surgery, such as axillary clearance for breast cancer or inguinal dissection for melanoma, or after radiotherapy that scars the lymphatic channels. Obstruction of lymph flow causes protein-rich fluid to accumulate in the tissue, leading to progressive swelling and fibrosis. The stagnant tissue is vulnerable to recurrent bacterial infection, such as cellulitis, which can further damage lymphatic vessels and worsen the cycle." }, { "heading": "Cancer metastasis and staging", "text": "Lymphatic spread to regional nodes\n\nMany carcinomas and melanomas spread first through the lymphatic system. Tumour cells can enter afferent lymphatic capillaries in or near the tumour, be carried in lymph, and lodge in the first nodes that receive that drainage. These regional nodes are often the first site of spread, which is why nodal status is assessed early in the management of many solid tumours. Spread to a node can occur before any tumour is palpable or visible on imaging. Nodes also act as a filter: a node can trap tumour cells without being fully replaced, and the tumour may then grow within the node or pass beyond it. The pattern of nodal involvement therefore depends on the organ's drainage pathways, which are described elsewhere in this article.\n\nNodal status in prognosis and TNM staging\n\nNodal involvement is one of the most important prognostic factors in oncology. In the TNM system developed by the American Joint Committee on Cancer and the Union for International Cancer Control, the T category describes the primary tumour, the N category describes regional nodal spread, and the M category describes distant metastasis. The N category is usually based on which nodes are involved and how many are involved. For example, in colorectal cancer, one to three positive nodes count as N1 and four or more as N2, with N2 further subdivided by the number of positive nodes in the 8th edition.\n\nNodal location matters as much as nodal count. Involvement of non-regional nodes is classified as distant metastasis even when the disease is otherwise confined to lymph nodes, so knowing each organ's regional drainage is essential for correct staging. Staging also depends on how many nodes are examined. A low number of examined nodes can lead to understaging, a phenomenon known as stage migration. For colorectal cancer, guidelines recommend examining at least 12 nodes for accurate N staging. Some researchers have proposed alternative measures, such as the lymph node ratio (the proportion of positive nodes among those examined), which in some studies predicted survival better than the conventional N category.\n\nThe sentinel lymph node concept\n\nThe sentinel lymph node is the first node that receives lymph directly from a tumour. If this node is free of tumour, the rest of the regional basin is generally considered free as well. The idea was discussed for decades before it reached routine practice. Ramon Cabanas introduced the technique in 1977, and in 1992 Donald Morton and colleagues at the John Wayne Cancer Institute described an operative procedure for melanoma. Their method combined preoperative lymphoscintigraphy using a radiotracer, intraoperative injection of blue dye, and histological examination of the identified node. Their first report included 237 patients and achieved an identification rate of 82%.\n\nSentinel node biopsy has since become the standard staging approach for early melanoma and is also used in breast cancer and other solid tumours. It allows the surgeon to avoid routine complete lymph node dissection in patients whose sentinel node is negative. If the sentinel node contains tumour, completion dissection of the regional basin may be considered, though the value of routine completion dissection has been studied in randomised trials for melanoma.\n\nLimits of node-based staging\n\nNode-based staging has several recognised limitations. Micrometastases, which are very small deposits of tumour cells, may be missed by standard haematoxylin and eosin staining and may only be found with immunohistochemistry or molecular methods. Nodes may also be classified as negative when they contain only a few tumour cells, and the clinical significance of such findings is still debated.\n\nFalse negatives are a particular concern for the sentinel node concept. In early melanoma the false-negative rate of the technique was reported at about 5%, but the rate depends on the number of nodes removed. In the NSABP B-32 trial for breast cancer, the false-negative rate was 17.7% when one sentinel node was removed, 10% for two nodes and 4.8% for three or more. Neoadjuvant chemotherapy adds further complexity. Some patients have a complete pathological response in the primary tumour while the nodes still contain disease, and some of the clinical scenarios in which the sentinel node is used after chemotherapy have produced false-negative rates above 10%. Reported figures vary widely between trials, and many clinicians consider a false-negative rate above 10% to be unacceptable. These issues mean that the reliability of node-based staging depends on the surgical technique, the number of nodes sampled, the pathology methods used, and whether the patient has received systemic therapy before surgery." }, { "heading": "History of discovery", "text": "Knowledge of lymph nodes grew out of the study of the lymphatic system as a whole, and for its first century the vessels drew more attention than the nodes. In 1622 the Milanese anatomist Gaspare Aselli saw thin white cords in living dogs. He first took them for nerves, but after repeated dissections he concluded that they formed a separate circulation carrying milky fluid, and he called them lacteals. His book appeared only in 1627, after his death. In 1651 Jean Pecquet traced these vessels to a reservoir (the cisterna chyli) and the thoracic duct, showing that they drained into the veins near the left subclavian vein rather than into the liver. This overturned the Galenic view that chyle was turned into blood in the liver. Thomas Bartholin confirmed the finding in humans in 1652 and named the vessels vasa lymphatica, the origin of the modern term. Olaus Rudbeck, working at about the same time, disputed Bartholin's priority for describing the general lymphatic network.\n\nNodes themselves came into focus later. Marcello Malpighi, using the microscope in the later seventeenth century, described the glands lying along the course of lymphatic vessels. He argued that they were not fibrous swellings, and he also described the white pulp of the spleen. Some historians credit him with the earliest descriptions of lymphoma-like disease. In 1774 William Hewson reported that nodes are absent in fishes, scarce in birds and largely present in mammals. He also suggested that the thymus and nodes produce a lymph full of globular particles, a forerunner of the modern lymphocyte. Paolo Mascagni, who injected mercury into lymphatic vessels, published in the 1780s a detailed illustration of the whole lymphatic network. Around the same time John Hunter and his collaborators in London clarified the function of the lymphatic system.\n\nIn the nineteenth century, pathologists began to study nodes as organs that changed in disease. Around 1900 gynaecologists observed that the pelvic nodes often enlarged in cervical cancer even without visible metastases. Microscopy showed sinus cell hyperplasia and large lymphoid follicles with germinal centres in these nodes. Attention to the link between nodes and cancer spread grew from such observations. In the twentieth century, immunology made nodes central to the adaptive immune response. In 1964 Gowans and Knight described how lymphocytes are directed into nodes, which established the recirculation of these cells between blood and lymph. Nodes were then understood as the places where antigen-bearing cells meet and activate lymphocytes.\n\nThe sentinel node concept developed from these threads. The American surgeon Ernest Gould used the term \"sentinel node\" in 1960, in a small series of parotid cancer patients. In 1977 the Paraguayan urologist Ramón Cabañas studied 46 patients with penile cancer using lymphangiography, and he identified the node that received drainage first from the tumour. If that node contained metastases, he recommended wider removal of regional nodes. Cabañas' anatomical model did not allow for individual variation in drainage routes, which led to many false negatives. In 1992 Donald Morton and colleagues in California used intradermal blue dye to map sentinel nodes in melanoma, with a high success rate and a low false-negative rate. Handheld gamma detectors, developed by Krag and others, allowed surgeons to locate radiolabelled nodes during operations. A multicentre trial by Morton and colleagues in 1999 confirmed the accuracy of the method, and sentinel node biopsy has since become standard care for early melanoma. Its adoption in breast and other cancers changed surgical practice by reducing the extent of routine lymph node dissection." }, { "heading": "Surgical and medical technologies", "text": "Lymphadenectomy\n\nSurgeons remove regional lymph nodes to stage cancer, to clear disease from a nodal basin, or both. For breast cancer, axillary lymph node dissection (ALND) has traditionally removed the level I and II nodes of the armpit. Its complications are the main reason surgeons now try to limit it. A prospective Sudanese series of 96 women reported numbness in about 22%, seroma in about 16%, lymphedema in about 9% and surgical-site infection in about 9% after ALND (sources-placeholder). Lymphedema after ALND is linked to the extent of dissection and to axillary radiotherapy, and a single-centre study identified smoking, radiotherapy and the removal of more than 18 nodes as independent risk factors. Once lymphedema develops, it is difficult to treat, which is why prevention has become a priority in surgical technique.\n\nFor colorectal cancer, surgeons remove the nodes along the mesenteric vessels that supply the tumour segment. The number of nodes examined by the pathologist is used as a quality indicator, with at least 12 nodes a commonly cited target. In melanoma, complete lymph node dissection (CLND) was once performed routinely after a positive finding. The randomized trials MSLT-II and DeCOG-SLT later showed that immediate CLND did not improve melanoma-specific or overall survival compared with a policy of observation and delayed dissection, and this has reduced the use of routine CLND in node-positive melanoma.\n\nSentinel node mapping\n\nThe sentinel lymph node is the first node that receives lymph from a tumour, and mapping it allows the surgeon to remove only a few nodes. Mapping usually combines a radioactive tracer with a blue dye. The tracer is injected near the tumour, pre-operative lymphoscintigraphy shows the likely drainage pathway, and a handheld probe that detects gamma rays guides the surgeon to the node. The blue dye, which is visible to the eye, marks the same node. Breast surgery protocols typically define sentinel nodes as those that are blue, radioactive or both, and they usually cap removal at about four nodes. A radiolabelled tracer based on tilmanocept has been compared with blue dye in phase 3 trials in melanoma and breast cancer, and indocyanine green fluorescence has been adopted in some trial protocols as an additional method.\n\nThe sentinel approach has changed how many nodes are removed. In two NCI-sponsored phase 3 trials, sentinel node biopsy without ALND was judged adequate for staging and for preventing regional recurrence in selected women with clinically node-negative breast cancer who received surgery, systemic therapy and radiotherapy. The INSEMA trial, published in 2024 with more than 5,500 patients, found that omitting sentinel node biopsy in low-risk, clinically node-negative disease did not reduce invasive disease-free survival, and axillary recurrence was below 1% in both arms. These results have pushed axillary surgery towards de-escalation, although the question of which patients can safely avoid nodal surgery remains under study.\n\nSurgical treatment of lymphedema\n\nMicrosurgery offers two main approaches for established lymphedema. Lymphovenous anastomosis (LVA) connects small lymphatic vessels to nearby venules so that lymph bypasses the blockage and drains into the venous system. Vascularized lymph node transfer (VLNT) moves a flap of lymph nodes with its blood supply, commonly from the groin, mesentery or omentum, into the affected limb, usually the axilla for arm lymphedema. Indocyanine green lymphography is used to decide between them: patients with patent lymphatic vessels are typically offered LVA, while those without patent vessels are offered VLNT. LVA is generally limited to earlier disease because it depends on functioning lymphatic channels, whereas VLNT does not require them and is often used in more advanced cases.\n\nEvidence on outcomes is growing but still limited in duration. A systematic review and meta-analysis of studies with at least two years of follow-up found that both procedures reduced the annual rate of cellulitis, which is a major source of morbidity in lymphedema. Reductions in limb volume and in the need for daily compression garments have also been reported. Most published series are small and retrospective, and comparisons between LVA and VLNT are inconsistent.\n\nNodal status in systemic and radiation planning\n\nLymph node status is one of the main determinants of further treatment after surgery. In breast cancer, axillary dissection is reserved for confirmed nodal involvement in early-stage disease, and the presence of nodal metastasis influences the extent of adjuvant chemotherapy, the choice of radiotherapy fields and whether regional nodes are irradiated. In melanoma and other solid tumours, nodal staging also determines eligibility for adjuvant immunotherapy in many guidelines. Because sentinel node results are often used to decide whether further surgery or treatment is needed, the accuracy of mapping has direct consequences for the treatment a patient receives." }, { "heading": "Research frontiers and open questions", "text": "Tertiary lymphoid structures in tumours\n\nOrganised immune aggregates are not confined to lymphoid organs. Researchers have found that tertiary lymphoid structures (TLS) arise after birth in tissues that normally lack them, mainly during chronic inflammation such as cancer, chronic infections, and autoimmune diseases. Their composition changes with maturity. Immature TLS show clearly visible foci of immune cells with segregated B and T cell zones, but lack follicular dendritic cells (FDCs) and germinal centres, whereas later stages acquire FDCs and then germinal centres, the sites of active B-cell proliferation and affinity maturation.\n\nThe functional picture is not uniform. TA-TLS of varying maturity, density, and location may have opposing effects on tumour immunity. Mature, dense structures are generally associated with better outcomes and response to checkpoint inhibitors, but in renal cell carcinoma TLS is heterogeneous, with their formation and function affected by factors like CXCL13 expression. Some studies have also linked germinal-centre activity to tumour control at the cellular level: in nasopharyngeal carcinoma, plasma cells matured in germinal centres were found to intersperse with tumour cell aggregates, promoting apoptosis of EBV-related malignant cells and enhancing immunotherapy response. Whether TLS are causal drivers of anti-tumour immunity or mainly markers of an active immune reaction remains unresolved.\n\nNode responses to cancer immunotherapy\n\nDraining nodes are now being studied as active partners in treatment rather than only as passive sites of spread. Tumour-draining nodes are critical sites for priming tumor-specific immune responses while also acting as conduits for cancer metastasis. In one study of checkpoint therapy, immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumour, and conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process.\n\nThese findings bear on surgery. Whether to remove nodes, and when to give immunotherapy relative to surgery, are three key clinical questions under active investigation in lung cancer. Some clinicians argue that node removal limits spread, while others hold that it may eliminate a compartment critical for systemic immune activation. Tumour signals can also reshape the node itself: tumor-derived signals remodel TDLNs, shifting them from an immune-activating to an immunosuppressive environment. Drug delivery is another line of work; in mice, targeted delivery of mAb to tumor-draining lymph nodes (TdLNs) alone was associated with enhanced antitumor immunity and improved therapeutic effects compared to conventional systemic ICB therapy.\n\nTumour cell entry and whether nodes drive metastasis\n\nThe first step of nodal spread is their entry into lymphatic vessels, a process called lymphatic vascular invasion (LVI). The molecular route is still incompletely mapped. Tumour cells may exploit at least some of the normal physiological mechanisms used by immune cells to access lymphatic capillaries. One proposed route involves hyaluronan and its receptors, and recent work suggests this axis may also be used by some tumours to aid nodal metastasis. Within the node, chemokines matter: secretion of CCL1 by lymphatic endothelial cells at the junction between the afferent lymphatics and the subcapsular sinus allows the entry of CCR8-expressing tumor cells into the node.\n\nThe more contested question is whether nodes merely record spread or help sustain it. More recently, lymph nodes were shown to provide sites of tumor cell entry into the blood circulation. This fits a model in which cancer cells may spread initially through the main gateway of the SLN, from which evolving cancer clones can invade the blood vessels to distant sites. Other cells may enter the blood vessels directly, bypassing the SLN to establish distant metastases. Settling this requires tracking individual clones over time, which is technically demanding.\n\nMeasuring node function and predicting response\n\nThere is no routine in vivo measure of how well a node is working. Experimental approaches include single-cell analysis and deep T cell receptor (TCR) sequencing, which can follow T cells moving between draining nodes and tumours. Motility is another candidate readout: studying T cell dynamics in TDLNs can provide a good indicator to evaluate the efficacy of antitumor therapy. Imaging-based approaches of this kind remain largely experimental, and no validated node-based measure is yet in clinical use.\n\nBiomarker work is more advanced for tissue signatures than for nodes. Researchers have reported that tertiary lymphoid structure-related cell signatures correlate with prognosis and PD-1 blockade response, and that the presence, maturity, and functionality of TLS may serve as valuable predictors of ICIs response and patient prognosis. Open questions include whether these signals hold across cancer types, whether node-level measures add predictive value beyond them, and whether treatment could deliberately build or preserve these structures." } ], "links": [ "lymphatic-system", "lymphocyte", "macrophage", "dendritic-cell", "adaptive-immunity", "antibody", "lymphoma", "cancer", "antigen", "spleen", "thymus", "bone-marrow", "b-cell", "germinal-center", "t-cell", "plasma-cell", "cytokine", "major-histocompatibility-complex", "t-cell-receptor", "immunological-memory", "affinity-maturation", "class-switch-recombination", "somatic-hypermutation", "transcription-factor", "hematopoiesis", "ultrasonography", "x-ray-computed-tomography", "magnetic-resonance-imaging", "pathology", "diagnosis", "virus", "autoimmune-disease", "leukemia", "lymphedema", "surgery", "radiation-therapy", "radioactivity", "gamma-ray", "chemotherapy", "cancer-immunotherapy", "immune-checkpoint" ], "sources": [ { "title": "Anatomy, Abdomen and Pelvis: Lymphatic Drainage", "url": "https://www.statpearls.com/point-of-care/32336" }, { "title": "Cervical lymph nodes: anatomy, groups and drainage", "url": "https://www.kenhub.com/en/library/anatomy/cervical-lymph-nodes" }, { "title": "Lymph nodes: Definition, anatomy and locations", "url": "https://www.kenhub.com/en/library/anatomy/lymph-nodes" }, { "title": "Lymph Node Exam", "url": "https://www.jove.com/v/10061/lymph-nodes-head-neck-axillae-upper-lower-extremities" }, { "title": "Axillary lymph nodes: Definition, anatomy and location", "url": "https://www.kenhub.com/en/library/anatomy/axillary-lymph-nodes" }, { "title": "Lymph nodes of the thorax and abdomen: Anatomy", "url": "https://www.kenhub.com/en/library/anatomy/lymph-nodes-of-the-thorax-and-abdomen" }, { "title": "Lymph node", "url": "https://en.wikipedia.org/wiki/Lymph_node" }, { "title": "List of lymph nodes of the human body", "url": "https://en.wikipedia.org/wiki/List_of_lymph_nodes_of_the_human_body" }, { "title": "How Many Lymph Nodes Are in the Body and Where? - ScienceInsights", "url": "https://scienceinsights.org/how-many-lymph-nodes-are-in-the-body-and-where/" }, { "title": "Lymphatic System Anatomy - Vessels - Nodes - Organs - TeachMeAnatomy", "url": "https://teachmeanatomy.info/the-basics/ultrastructure/lymphatic-system/" }, { "title": "Afferent Lymph Vessel - an overview", "url": "https://www.sciencedirect.com/topics/neuroscience/afferent-lymph-vessel" }, { "title": "Cortex of lymph node - e-Anatomy - IMAIOS", "url": "https://www.imaios.com/en/e-anatomy/anatomical-structures/cortex-of-lymph-node-116930176" }, { "title": "Lymph nodes: Histology", "url": "https://www.kenhub.com/en/library/anatomy/histology-of-lymph-nodes" }, { "title": "Lymph node 8", "url": "https://digitalhistology.org/organs-systems/lymphoid/organs/lymph-node/lymph-node-8/" }, { "title": "Normal Structure, Function, and Histology of Lymph Nodes - Cynthia L. Willard-Mack, 2006", "url": "https://journals.sagepub.com/doi/10.1080/01926230600867727" }, { "title": "Lymph node 1", "url": "https://digitalhistology.org/organs-systems/lymphoid/organs/lymph-node/lymph-node-1/" }, { "title": "Lymph nodes", "url": "https://histology.leeds.ac.uk/home/lymphoid/lymphnodes/" }, { "title": "🧬 Anatomy of a Lymph Node — King of the Curve", "url": "https://kingofthecurve.org/blog/anatomy-of-a-lymph-node" }, { "title": "Lymph nodes Definition and Examples - Biology Online Dictionary", "url": "https://www.biologyonline.com/dictionary/lymph-nodes" }, { "title": "Fibroblastic Reticular Cells: Organization and Regulation of the T Lymphocyte Life Cycle", "url": "https://journals.aai.org/jimmunol/article/194/4/1389/99556/Fibroblastic-Reticular-Cells-Organization-and" }, { "title": "Fibroblastic Reticular Cells From Lymph Nodes Attenuate T Cell Expansion by Producing Nitric Oxide", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215737/" }, { "title": "High-resolution 3D imaging and topological mapping of the lymph node conduit system", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922347/" }, { "title": "Lymph node fibroblastic reticular cells in health and disease - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5152733/" }, { "title": "Lymph node fibroblastic reticular cells steer immune responses: Trends in Immunology", "url": "https://www.cell.com/trends/immunology/fulltext/S1471-4906(21)00120-4" }, { "title": "Communication, construction, and fluid control: lymphoid organ fibroblastic reticular cell and conduit networks: Trends in Immunology", "url": "https://www.cell.com/trends/immunology/fulltext/S1471-4906(21)00138-1" }, { "title": "Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/17893676" }, { "title": "Lymph Node - an overview", "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/lymph-node" }, { "title": "Lymph node 2", "url": "https://digitalhistology.org/organs-systems/lymphoid/organs/lymph-node/lymph-node-2/" }, { "title": "Lymph node - WikiLectures", "url": "https://www.wikilectures.eu/w/Lymph_node" }, { "title": "Pathology Outlines - Anatomy & histology-lymph nodes", "url": "https://www.pathologyoutlines.com/topic/lymphnodesanatomy.html" }, { "title": "elsevier.com", "url": "https://elsevier.com/resources/anatomy/lymphoid-system/lymph-node/subcapsular-sinus/15237" }, { "title": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1167010" }, { "title": "Right Lymphatic Duct - an overview", "url": "https://www.sciencedirect.com/topics/neuroscience/right-lymphatic-duct" }, { "title": "Lymphatic system anatomy and physiology: Video", "url": "https://www.osmosis.org/learn/Lymphatic_system_anatomy_and_physiology" }, { "title": "Anatomy of the Lymphatic and Immune Systems", "url": "https://courses.lumenlearning.com/odessa-ap2/chapter/anatomy-of-the-lymphatic-and-immune-systems/" }, { "title": "Lymph Flow - an overview", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/lymph-flow" }, { "title": "21.1 Anatomy of the Lymphatic and Immune Systems - Anatomy and Physiology 2e", "url": "https://openstax.org/books/anatomy-and-physiology-2e/pages/21-1-anatomy-of-the-lymphatic-and-immune-systems" }, { "title": "19.3: Anatomy of Lymphatic Vessels - Medicine LibreTexts", "url": "https://med.libretexts.org/Bookshelves/Anatomy_and_Physiology/Human_Anatomy_(OERI)/19:_Lymphatic_and_Immune_System/19.03:_Anatomy_of_Lymphatic_Vessels" }, { "title": "Intravital Two-Photon Imaging of Lymphocytes Crossing High Endothelial Venules and Cortical Lymphatics in the Inguinal Lymph Node", "url": "https://link.springer.com/protocol/10.1007/978-1-4939-3480-5_15" }, { "title": "CC chemokine receptor 7 required for T lymphocyte exit from peripheral tissues - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2144916/" }, { "title": "High-endothelial cell-derived S1P regulates dendritic cell localization and vascular integrity in the lymph node", "url": "https://elifesciences.org/articles/41239" }, { "title": "Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization", "url": "https://ashpublications.org/blood/article/119/4/978/29721/Lymph-node-B-lymphocyte-trafficking-is-constrained" }, { "title": "High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes", "url": "https://ashpublications.org/blood/article/118/23/6115/29118/High-endothelial-venules-as-traffic-control-points" }, { "title": "High-endothelial cell-derived S1P regulates dendritic cell localization and vascular integrity in the lymph node", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773441/" }, { "title": "Lymphocyte Recirculation - an overview", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lymphocyte-recirculation" }, { "title": "The lymphatic endothelial-immune dialogue in cancer and immunotherapy", "url": "https://www.sciexplor.com/exo/articles/EXO.2026.0007" }, { "title": "The follicular dendritic cell: At the germinal center of autoimmunity?: Cell Reports", "url": "https://www.cell.com/cell-reports/fulltext/S2211-1247(24)00197-9" }, { "title": "Circulating Follicular Helper and Follicular Regulatory T Cells Are Severely Compromised in Human CD40 Deficiency: A Case Report", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090258/" }, { "title": "Follicular Dendritic Cells Modulate Germinal Center B Cell Diversity through FcγRIIB: Cell Reports", "url": "https://www.cell.com/cell-reports/fulltext/S2211-1247(19)31408-1" }, { "title": "Regulated somatic hypermutation enhances antibody affinity maturation", "url": "https://www.nature.com/articles/s41586-025-08728-2" }, { "title": "How do follicular dendritic cells interact intimately with B cells in the germinal centre? - Park - 2005 - Immunology - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2567.2004.02075.x" }, { "title": "Germinal Center - an overview", "url": "https://www.sciencedirect.com/topics/neuroscience/germinal-center" }, { "title": "Highlight of 2023: Advances in germinal centers - Pankhurst - 2024 - Immunology & Cell Biology - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/imcb.12800" }, { "title": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3674076" }, { "title": "Sox18 induces development of the lymphatic vasculature in mice - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/18931657/" }, { "title": "Key Points", "url": "https://link.springer.com/article/10.1038/nri2832" }, { "title": "Lymphoid tissue inducer cells: architects of CD4 immune responses in mice and men - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2710588/" }, { "title": "link.springer.com", "url": "https://link.springer.com/10.1038/srep40401" }, { "title": "Frontiers", "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00013/full" }, { "title": "The early postnatal development of the primary immune response in TNP-KLH-stimulated popliteal lymph node in the rat - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/3791388/" }, { "title": "A Fresh View on Lymph Node Organogenesis: Trends in Immunology", "url": "https://www.cell.com/trends/immunology/abstract/S1471-4906(18)30149-2" }, { "title": "Lymphoid tissue inducer cells: Current Biology", "url": "https://www.cell.com/current-biology/fulltext/S0960-9822(11)00294-6" }, { "title": "Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3539229/" }, { "title": "Stromal Cell Subsets Directing Neonatal Spleen Regeneration", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220291/" }, { "title": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3582116" }, { "title": "Sox18 induces development of the lymphatic vasculature in mice", "url": "https://www.researchgate.net/publication/23395248_Sox18_induces_development_of_the_lymphatic_vasculature_in_mice" }, { "title": "Lymphadenopathy - Knowledge @ AMBOSS", "url": "https://www.amboss.com/us/knowledge/lymphadenopathy" }, { "title": "Lymphadenopathy - Cardiology - Merck Manual Professional Edition", "url": "https://www.merckmanuals.com/professional/cardiovascular-disorders/lymphatic-disorders/lymphadenopathy" }, { "title": "Pediatric Lymph Node Disorders Clinical Presentation: History, Physical Examination, Risk Stratification", "url": "https://emedicine.medscape.com/article/937855-clinical" }, { "title": "Lymphadenopathy Clinical Presentation: History, Physical, Causes", "url": "https://emedicine.medscape.com/article/956340-clinical" }, { "title": "Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis", "url": "https://www.aafp.org/pubs/afp/issues/2016/1201/p896.html" }, { "title": "The Evaluation of Lymphadenopathy in a Resource-Limited Setting", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681672/" }, { "title": "LYMPHADENOPATHY APRN/PA Pediatric Updates in Clinical Practice", "url": "https://www.akronchildrens.org/inside/wp-content/uploads/2024/05/Lymphadenopathy.pdf" }, { "title": "Radiologic Assessment of Lymph Nodes in Oncologic Patients", "url": "https://link.springer.com/article/10.1007/s40134-013-0036-6" }, { "title": "PET and CT features differentiating infectious/inflammatory from malignant mediastinal lymphadenopathy: A correlated study with endobronchial ultrasound-guided transbronchial needle aspiration - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/pii/S2352621117300967" }, { "title": "Accuracy of 18F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer", "url": "https://ajronline.org/doi/10.2214/AJR.07.3372" }, { "title": "PET-CT Imaging of Lymphoma - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7120336/" }, { "title": "Optimizing the diagnosis of pelvic lymph node metastasis in bladder cancer using computed tomography and magnetic resonance imaging", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892386/" }, { "title": "Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/25611108/" }, { "title": "Establishing the Diagnosis of Lymphoma: From Initial Biopsy to Clinical Staging", "url": "https://www.cancernetwork.com/view/establishing-diagnosis-lymphoma-initial-biopsy-clinical-staging" }, { "title": "Analysis of efficacy and safety of core-needle biopsy versus fine-needle aspiration cytology in patients with cervical lymphadenopathy and salivary gland tumour - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0901502718301334" }, { "title": "Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932200/" }, { "title": "Pathology Outlines - Reactive lymphadenopathy", "url": "https://www.pathologyoutlines.com/topic/lymphnodesreactivegeneral.html" }, { "title": "Cervical reactive lymphadenopathy", "url": "https://www.vinmec.com/eng/blog/reactive-lymphadenitis-of-the-neck-en" }, { "title": "Reactive lymphadenopathy in daily practice", "url": "https://taurunummedicaljournal.com/article/214" }, { "title": "A Case of Reactive Cervical Lymphadenopathy with Fat Necrosis Impinging on Adjacent Vascular Structures - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5093268/" }, { "title": "Sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman disease) in an HIV-positive patient", "url": "https://link.springer.com/article/10.1007/BF01626356" }, { "title": "A Review of the Sub-Classification of Lymph Node Biopsies Reported as Reactive Lymphadenitis at Kenyatta National Hospital, Kenya", "url": "https://clinmedjournals.org/articles/ijpcr/international-journal-of-pathology-and-clinical-research-ijpcr-7-120.php?jid=ijpcr" }, { "title": "Rosai-Dorfman Disease: Case Series and Literature Review", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030647/" }, { "title": "Rosaï-Dorfman-Destombes Disease: A Clinical Case Report", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793844/" }, { "title": "Rosai-Dorfman Disease: Self-Resolving Unilateral Lymphadenopathy and a Brief Review of Literature", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165585/" }, { "title": "Kikuchi–Fujimoto Disease: A Case Series and Review of the Literature", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592699/" }, { "title": "Pathological Features and Clinical Characteristics of Kikuchi-Fujimoto Disease: A Tertiary Hospital Experience in Riyadh, Saudi Arabia", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835018/" }, { "title": "Kikuchi‐Fujimoto disease: investigating comprehensive clinicopathological features and risk factors for recurrence - Nishimura - 2025 - Histopathology - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/his.15427" }, { "title": "Clinicopathological Characteristics of Kikuchi-Fujimoto Disease: A Retrospective Case Series from Pakistan - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13322459/" }, { "title": "A pattern-based approach to reactive lymphadenopathies - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0740257017300606" }, { "title": "Pathological Features and Clinical Characteristics of Kikuchi-Fujimoto Disease: A Tertiary Hospital Experience in Riyadh, Saudi Arabia - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9835018/" }, { "title": "Kikuchi‐Fujimoto disease: investigating comprehensive clinicopathological features and risk factors for recurrence - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12129606" }, { "title": "Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease): Imaging Manifestations in the Head and Neck", "url": "https://ajronline.org/doi/10.2214/AJR.08.1114" }, { "title": "Concomitant sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman Disease) and diffuse large B-cell lymphoma: a case report", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270859/" }, { "title": "Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6244615/" }, { "title": "Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9698247/" }, { "title": "The Journey of Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Brief Narrative Review from Scalpel to Smart Tech - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12471994" }, { "title": "Sentinel Lymph Node Biopsy for Melanoma - Clinical Tree", "url": "https://clinicalpub.com/sentinel-lymph-node-biopsy-for-melanoma/" }, { "title": "Sentinel Lymph Node Biopsy in Melanoma", "url": "https://jnm.snmjournals.org/content/47/2/191" }, { "title": "Understanding the Lymphatics: Review of the N Category in the Updated TNM Staging of Cancers of the Digestive System", "url": "https://www.ajronline.org/doi/10.2214/AJR.19.22636" }, { "title": "A Comprehensive Evaluation of Lymph Node Staging and a Proposal to Subdivide N2b Category in Colorectal Cancer Patients", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12730854/" }, { "title": "Metastatic lymph node ratio demonstrates better prognostic stratification than pN staging in patients with esophageal squamous cell carcinoma after esophagectomy", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150247/" }, { "title": "Metastatic lymph node in gastric cancer; Is it a real distant metastasis?", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848187/" }, { "title": "Sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with breast cancer: Are the current false negative rates acceptable? - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/25800381/" }, { "title": "Full article: Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Breast Cancer", "url": "https://www.tandfonline.com/doi/full/10.2217/bmt.15.25" }, { "title": "Use of Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients with node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5759951" }, { "title": "The lymphatic system throughout history: From hieroglyphic translations to state of the art radiological techniques - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9542037/" }, { "title": "The Lymphatic System: A Historical Perspective", "url": "https://www.researchgate.net/publication/51100517_The_Lymphatic_System_A_Historical_Perspective" }, { "title": "Scholars and scientists in the history of the lymphatic system - Natale - 2017 - Journal of Anatomy - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/joa.12644" }, { "title": "The discovery of lymphatic system in the seventeenth century. Part I: The early history", "url": "https://www.researchgate.net/publication/303778590_The_discovery_of_lymphatic_system_in_the_seventeenth_century_Part_I_The_early_history" }, { "title": "Lymphatics", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261540/" }, { "title": "The Lymphatic System, Considered in Relation to Its Anatomy, Physiology, and Pathology", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595510/" }, { "title": "Date Events and discoveries that advanced lymphatic research 1600 B.C.E.", "url": "https://dm5migu4zj3pb.cloudfront.net/manuscripts/171000/171582/JCI171582.sd.pdf" }, { "title": "(PDF) Historical Landmarks in an Understanding of the Lymphomas", "url": "https://www.researchgate.net/publication/323787807_Historical_Landmarks_in_an_Understanding_of_the_Lymphomas" }, { "title": "Sinus Cell Hyperplasia of Lymph Nodes Regional to Adenocarcinoma of the Breast and Colon", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074093/" }, { "title": "Sentinel Node Methods in Penile Cancer", "url": "https://www.sciencedirect.com/science/article/pii/S0001299821000970" }, { "title": "Current Status of Sentinel Lymph Node Mapping and Biopsy: Facts and Controversies", "url": "https://doi.org/10.1634/theoncologist.8-1-59" }, { "title": "Sentinel lymph node biopsy in penile carcinoma - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0740257011001006" }, { "title": "Sentinel node biopsy for melanoma: Where have we been and where are we going?", "url": "https://link.springer.com/article/10.1007/BF02523619" }, { "title": "Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma", "url": "https://clinicaltrials.gov/study/NCT00671918" }, { "title": "Sentinel Lymph Node Biopsy", "url": "https://melanomasurgery.ucsf.edu/procedure/sentinel-lymph-node-biopsy" }, { "title": "Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.", "url": "https://cdn.clinicaltrials.gov/large-docs/72/NCT02240472/Prot_000.pdf" }, { "title": "Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9475390/" }, { "title": "The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817613/" }, { "title": "Lessons from the INSEMA trial: is sentinel lymph node biopsy in early-stage breast cancer stepping off the stage?", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014572/" }, { "title": "Axillary Lymph Node Dissection for Breast Cancer", "url": "https://www.moffitt.org/cancers/breast-cancer/treatment/axillary-lymph-node-dissection/" }, { "title": "Lymphedema following axillary lymph node dissection for breast cancer - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/17187979/" }, { "title": "Lymphedema After Axillary Lymph Node Dissection in Breast Cancer: Prevalence and Risk Factors—A Single-Center Retrospective Study - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9810350/" }, { "title": "Axillary Lymph Node Dissection for Breast Cancer: Efficacy and Complication in Developing Countries", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223503/" }, { "title": "Breast Cancer and Axillary Lymph Node Dissection", "url": "https://www.breastcancer.org/treatment/surgery/lymph-node-removal/axillary-dissection" }, { "title": "Lymphovenous Anastomosis and Vascularized Lymph Node Transfer Reduce Long-term Cellulitis Events in Patients With Secondary Lymphedema: A Systematic Review and Meta-analysis - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/41071856/" }, { "title": "Objectifying Clinical Outcomes After Lymphaticovenous Anastomosis and Vascularized Lymph Node Transfer in the Treatment of Extremity Lymphedema: A Systematic Review and Meta‐Analysis", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895410/" }, { "title": "Improving quality of life after breast cancer: a comparison of two microsurgical treatment options for breast cancer-related lymphedema (BCRL)", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039536/" }, { "title": "Lymphaticovenous Anastomosis and Vascularized Lymph Node Transfer for the Treatment of Lymphedema-A Canadian Case Series - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/38681252" }, { "title": "Outcomes of Vascularized Lymph Node Transfer and Lymphovenous Anastomosis for Treatment of Primary Lymphedema - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6326612/" }, { "title": "Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998345/" }, { "title": "Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149953/" }, { "title": "Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12498089/" }, { "title": "Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375053/" }, { "title": "Tumor-draining lymph nodes", "url": "https://www.sciencedirect.com/science/article/pii/S2405803325001049" }, { "title": "Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12501088/" }, { "title": "Tumor-specific draining lymph node CD8 T cells orchestrate an anti-tumor response to neoadjuvant PD-1 immune checkpoint blockade", "url": "https://www.biorxiv.org/content/10.1101/2025.04.27.650862.full.pdf" }, { "title": "Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377700/" }, { "title": "Mechanisms and Clinical Significance of Tumor Lymphatic Invasion", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533989/" }, { "title": "Lymphatic trafficking of immune cells and insights for cancer metastasis", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374813/" }, { "title": "Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5496496/" }, { "title": "Lymphatic Vessels in Tumor Dissemination versus Immunotherapy", "url": "https://aacrjournals.org/cancerres/article/80/17/3463/645836/Lymphatic-Vessels-in-Tumor-Dissemination-versus" }, { "title": "Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967809/" }, { "title": "Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465463/" } ], "license": "https://creativecommons.org/licenses/by/4.0/" }